Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT00037869 | High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors | completed | Phase 3 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| Cabergoline in Nonfunctioning Pituitary Adenomas |
| completed |
| Phase 3 |
| 140 |
| University of Sao Paulo General HospitalOTHER |
| 1 |
| Sep 7, 2017 |
| clinicaltrials |
| NCT00717938 | A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer(RASTEN) | completed | Phase 3 | 390 | Lund University HospitalOTHER | 1 | Aug 25, 2017 | clinicaltrials |
| NCT00320359 | Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer | completed | Phase 3 | 700 | GlaxoSmithKlineINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT00144989 | A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC | completed | Phase 3 | 281 | Haruhiko FukudaOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00930891 | Bevacizumab in Extensive Small Cell Lung Cancer(CPC) | completed | Phase 2 / Phase 3 | 143 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00658580 | Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer | completed | Phase 3 | 361 | European Lung Cancer Working PartyOTHER | 4 | Feb 12, 2015 | clinicaltrials |
| NCT00412061 | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor(RADIANT-2) | completed | Phase 3 | 429 | Novartis PharmaceuticalsINDUSTRY | 15 | Nov 21, 2014 | clinicaltrials |
| NCT00002641 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | completed | Phase 3 | 350 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Aug 8, 2014 | clinicaltrials |
| NCT00349492 | A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer | completed | Phase 3 | 372 | Clinical Research Center for Solid Tumor, KoreaOTHER | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00043927 | Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults | completed | Phase 3 | 760 | GlaxoSmithKlineINDUSTRY | 34 | Aug 21, 2013 | clinicaltrials |
| NCT01125995 | Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer | completed | Phase 3 | 222 | Samsung Medical CenterOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00276276 | Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer | completed | Phase 3 | 141 | GlaxoSmithKlineINDUSTRY | 6 | Apr 15, 2013 | clinicaltrials |
| NCT00002764 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | completed | Phase 3 | 340 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 11, 2012 | clinicaltrials |
| NCT00270166 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | completed | Phase 3 | 201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00037713 | Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG | completed | Phase 3 | 515 | Eli Lilly and CompanyINDUSTRY | 0 | Apr 8, 2010 | clinicaltrials |
| NCT00143455 | Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer | completed | Phase 3 | 485 | PfizerINDUSTRY | 13 | Feb 18, 2010 | clinicaltrials |
| NCT00363415 | Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 908 | Eli Lilly and CompanyINDUSTRY | 26 | Oct 28, 2009 | clinicaltrials |
| NCT00290953 | Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide(SESAME) | completed | Phase 2 / Phase 3 | 432 | SanofiINDUSTRY | 14 | Dec 23, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Jan 25, 2019source: clinicaltrials